Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pantoprazole
Autore:
Poole, P;
Indirizzi:
Univ Calif Davis, Med Ctr, Dept Pharmaceut Sci, Sacramento, CA 95817 USA Univ Calif Davis Sacramento CA USA 95817 ut Sci, Sacramento, CA 95817 USA
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
fascicolo: 11, volume: 58, anno: 2001,
pagine: 999 - 1008
SICI:
1079-2082(20010601)58:11<999:P>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTON-PUMP INHIBITORS; HELICOBACTER-PYLORI INFECTION; GASTRIC-ACID SECRETION; GASTROESOPHAGEAL REFLUX DISEASE; ACUTE DUODENAL-ULCER; TRIPLE THERAPY; INTRAGASTRIC PH; MULTICENTER TRIAL; OMEPRAZOLE; ESOPHAGITIS;
Keywords:
dosage; esophagitis; gastroesophageal reflux; mechanism of action; pantoprazole sodium; pharmacokinetics; toxicity;
Tipo documento:
Reprint
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Poole, P Univ Hlth Syst Consortium, 2001 spring Rd,Suite 700, Oak Brook, IL 60523 USA Univ Hlth Syst Consortium 2001 spring Rd,Suite 700 Oak Brook ILUSA 60523
Citazione:
P. Poole, "Pantoprazole", AM J HEAL S, 58(11), 2001, pp. 999-1008

Abstract

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pantoprazole are reviewed. Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) inhibitor. It shares the same core structure as other currently available proton-pump inhibitors (PPIs). The FDA-labeled indication is the short-term treatment of erosive esophagitis. PPIs act by selectively inhibiting H+/K+-ATPase in the secretory canaliculus of the stimulated parietal cell. Understanding the pharmacodynamics of PPIs is more relevant than knowing their pharmacokinetics, since the duration of action depends on the rateof de novo proton-pump regeneration not the duration of drug circulation in the body. Pantoprazole is well absorbed, undergoes little first-pass metabolism, and has an absolute bioavailability of approximately 77%. Pantoprazole has been evaluated in more than 100 clinical trials involving more than11,000 patients. It is effective in treating erosive esophagitis and duodenal and gastric ulcers. It is also effective as adjunctive treatment with antimicrobials in patients infected with Helicobacter pylori. Pantoprazole has been shown to control acid production in Zollinger-Ellison syndrome. Pantoprazole is well tolerated. The most commonly reported adverse effects areheadache, diarrhea, and abdominal pain. The recommended oral dosage for erosive esophagitis is 40 mg once a day for up to eight weeks. The recommended i.v. dose is 40 mg given over 15 minutes once a day in patients with gastroesophageal reflux disease who are unable to take oral medication. Pantoprazole appears to be as safe and effective as other PPIs in acid-related disorders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 02:43:55